Henrik Sune Ramírez-Andersen is a Scientific Director in Research Chemistry, GRT at Novo Nordisk A/S in Copenhagen, Denmark. Since 1989, Henrik Sune has worked for Novo Nordisk within type 2 diabetes, obesity, inflammation, haemophilia, and growth hormone disorders, which has resulted in more than 70 patent and patent applications and 26 peer-reviewed scientific papers.
He has spent over 15 years as a department manager focusing on small molecule, peptide and protein medicinal chemistry. In recent years, Henrik Sune’s time has mostly been spent on external collaborations, as well as peptide and protein modification technologies aiming at new drug modalities.
In 2007-2008, he spent one year as department head at Zealand Pharma working on peptide synthesis and pre-formulation.
He graduated in 1989 from the Technical University of Denmark as Chemical Engineer with focus on heterocyclic organic chemistry and medicinal chemistry.